Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker Buys ACADIA

By
A A A

Welcome to our daily roundup of top insider trades. Here's a look at the most significant inside sales and purchases filed with the SEC on Friday, May 17, 2013.

Purchases: Felix Baker, a Director of biopharmaceutical company ACADIA Pharmaceuticals Inc. ( ACAD ), bought 1,993,000 shares of company stock for $24,912,500. Baker also serves as a Director of biotechnology company Seattle Genetics ( SGEN ) and molecular diagnostics company Genomic Health ( GHDX ), of which he has bought 535,796 shares of in 2013, worth almost $20 million. He also serves as Chairman of the clinical-stage biopharmaceutical company Synageva BioPharma ( GEVA ). ACADIA focuses on small molecule drugs that are meant to address unmet needs, especially in neurological and central nervous system disorders. As of today, the company is becoming part of the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI). On May 16, the company announced a public offering of 8 million shares of common stock for $12.50 per share; the offering is expected to close today, and the company is expecting proceeds of $100 million. The company's stock price has increased 185.38% year-to-date and 834.51% since this time last year.

The New York-based hedge fund Glenhill Advisors bought 342,350 shares of global software solutions company Lionbridge Technologies, Inc. ( LIOX ) for $881,205. Lionbridge providers its clients with language, content, and testing solutions that allow them to manage and optimize their technology applications and content in global markets. On May 8, the company announced Q1 2013 earnings with a GAAP net loss of $0.05 per share on revenue of $113.7 million, compared to a loss per share of $0.13 on revenue of $112.1 million in Q1 2012. The company's stock price has decreased 30.6% YTD and has decreased 7% since this time last year.

Phillip Frost, the Chairman and CEO of multi-national pharmaceutical and diagnostics company OPKO Health (OPK), bought 59,100 shares of company stock for $414,987. OPKO is developing an array of solutions for diagnosing, treating, and preventing various conditions, developing in particular molecular diagnostics tests, point-of-care tests, pharmaceuticals, and vaccines. Frost is a former professor of dermatology who got his start in big pharma when he took over Key Pharmaceuticals in 1972; he is also the Chairman of the Board of global pharmaceutical and drug company Teva Pharmaceutical Industries (TEVA). On April 24, OPKO announced that it would be acquiring the Israeli biopharma company PROLOR Biotech (NYSEMKT:PBTH). Since then, Frost has been buying shares of both companies (he is the majority shareholder of both) to prop up the deal, which is valued at $480 million and is expected to close in the second half of 2013. OPKO's stock price is up 48.86% YTD and up 59.47% since this time last year.

Robert Locascio, the Chairman and CEO of online engagement solutions company LivePerson (LPSN), bought 35,640 shares of company stock for $305,078. The company offers its clients a cloud-based platform that enables them to connect with consumers through chat, voice, and content delivery across websites, social media, and mobile devices. On May 8, the company reported Q1 2013 earnings per share of $0.06 on revenue of $38.9 million, missing consensus estimates of $0.07 per share and $42.54 million, respectively.

Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value

1

Baker Felix

DIR,BO


Acadia Pharm

ACAD

JB*

$24,912,500

2

Glenhill Advisors

BO

Lionbridge Tech

LIOX

B

$881,205

3

Frost Phillip Md

CEO,CB,BO

Opko Health

OPK

B

$414,987

4

Locascio Robert P

CEO,DIR

Liveperson

LPSN

B

$305,078

5

Mehmel Robert F

PR,COO

Griffon

GFF

B

$221,602

6

Wilson Christopher

GC,VP,SEC

General Finance

GFN

JB*

$210,000

7

Wesemann William

DIR

Liveperson

LPSN

B

$173,400

8

Shearer Mark

VP,PR

Pitney Bowes

PBI

B

$146,700

9

Bailey Douglas G

PR,CEO,CB

Fuel Tech

FTEK

B

$146,540

10

Jones L Blake

DIR

First NBC Bank

NBCB

JB*

$144,000


Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value

1

Fifth Third Banc

DIR,BO

Vantiv

VNTV

JS*

$375,783,744

2

Tmg Cooperatief

DIR,BO

Tornier

TRNX

JS*

$40,580,912

3

Johnson Rupert

VCB,DIR,BO

Franklin Resources

BEN

S

$25,065,000

4

Alon Israel Oil

BO

Alon Usa Energy

ALJ

S

$17,317,500

5

Wilson Dennis J

DIR,BO

Lululemon Athletica

LULU

AS

$16,566,278

6

Frink Lloyd D

VCB,PR,BO

Zillow

Z

S

$5,635,467

7

Inkinen Sami

DIR

Trulia

TRLA

S

$4,541,852

8

Crowe James Q

DIR

Level 3 Comms

LVLT

S

$3,843,625

9

Emmett Dan A

CB,DIR

Douglas Emmett

DEI

AS

$3,831,609

10

Emmitt Richard B

DIR

Tornier

TRNX

JS*

$3,528,775

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

An important note from Jonathan Moreland, founder of Insider Insights :

In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as "insiders."

Please note, however, that the lists above are strictly factual; they are not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

Jonathan Moreland is also the author of " Profit From Legal Insider Trading."

Follow me on Twitter: @JoshWolonick and @Minyanville



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Stocks

Referenced Stocks: ACAD , GEVA , GHDX , LIOX , SGEN

Minyanville

Minyanville

More from Minyanville:

Related Videos

Stocks

Referenced

Most Active by Volume

69,589,453
  • $17.71 ▲ 0.51%
67,826,144
  • $92.90 ▼ 14.34%
43,457,267
  • $7.15 ▲ 5.61%
41,474,187
  • $112.94 ▲ 1.04%
39,656,564
  • $7.45 ▲ 4.78%
38,604,858
  • $15.49 ▲ 9.01%
34,600,059
  • $25.71 ▲ 0.35%
32,095,432
  • $104.58 ▲ 0.25%
As of 12/22/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com